<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00538512</url>
  </required_header>
  <id_info>
    <org_study_id>FLUVACS</org_study_id>
    <nct_id>NCT00538512</nct_id>
  </id_info>
  <brief_title>Comparative Study of Influenza Vaccines in Adults, FLUVACS-year 4</brief_title>
  <acronym>FLUVACS</acronym>
  <official_title>Comparative Study of Influenza Vaccines in Adults, FLUVACS-year 4</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Michigan</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Sanofi Pasteur, a Sanofi Company</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Michigan</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the absolute (versus placebo) and relative (one
      vaccine compared to the other) efficacies of the live attenuated and inactivated influenza
      vaccines in preventing laboratory confirmed symptomatic influenza caused by circulating
      strains whether similar or dissimilar to strains included in the vaccines.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>September 2007</start_date>
  <completion_date type="Actual">May 2008</completion_date>
  <primary_completion_date type="Actual">May 2008</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Double (Participant, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Laboratory-confirmed (Culture and/or PCR) Symptomatic Influenza</measure>
    <time_frame>one influenza season - 2007-2008</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Measure Immune Response Induced by the Vaccines and Identify Serologic Correlates of Immune Protection</measure>
    <time_frame>Time between prevaccination visit and postvaccination visit; typically about 30 days.</time_frame>
    <description>Measure immune response induced by the vaccines. Response was defined as greater than or equal to 4 fold rise in antibody titers measured by hemagglutination inhibition (HAI), microneutralization (MN), or neuraminidase inhibition (NAI) assays between sera collected at the prevaccination visit and those collected at the postvaccination visit.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Immune Response to Vaccination and Infection</measure>
    <time_frame>Postvaccination to postseason visit; typically about 3 months.</time_frame>
    <description>Response was defined as greater than or equal to 4 fold rise in antibody titers measured by hemagglutination inhibition (HAI), microneutralization (MN), or neuraminidase inhibition (NAI) assays between sera collected at the postvaccination visit and those collected at the postseason visit.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Identify Serologic Correlates of Immune Protection. Suggest Changing to: Number of Participants Demonstrating Postvaccination Seroconversion.</measure>
    <time_frame>Time between prevaccination and postvaccination, typically about 30 days.</time_frame>
    <description>Identify serologic correlates of immune protection. Seroconversion is defined as either prevaccination titer of less than 8 and postvaccination titer of greater than or equal to 32 or prevaccination titer of greater than or equal to 8 and greater than or equal to 4 fold rise in strain specific hemagglutination-inhibition (HAI) antibody titer between prevaccination and postvaccination sera. Data is shown separately for cases (subjects with symptomatic influenza A laboratory confirmed by isolation in cell culture or identification in real-time polymerase chain reaction (PCR) assay) and non-cases (subjects without cell culture, real time PCR or serologic evidence of influenza infection).</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">1952</enrollment>
  <condition>Influenza</condition>
  <arm_group>
    <arm_group_label>TIV</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>the trivalent inactivated influenza vaccine - Fluzone, manufactured by Sanofi-Pasteur</description>
  </arm_group>
  <arm_group>
    <arm_group_label>LAIV</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>live-attenuated influenza vaccine Flumist, manufactured by MedImmune</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Physiologic saline administered as a nasal spray or intramuscular injection</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Fluzone</intervention_name>
    <description>single dose licensed trivalent inactivated influenza vaccine (2007-08)</description>
    <arm_group_label>TIV</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Flumist</intervention_name>
    <description>single dose licensed live-attenuated influenza vaccine Flumist (2007-08)</description>
    <arm_group_label>LAIV</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Physiologic saline</intervention_name>
    <description>single dose placebo administered as an intranasal spray or intramuscular injection</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Healthy adult men and women

          -  Age 18-49 years

          -  Who reside geographically close to one of the four study sites in Michigan

        Exclusion Criteria:

          -  Persons with any of the health conditions for which the inactivated vaccine is
             recommended

          -  Persons for whom either vaccine is contraindicated
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>49 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Arnold S. Monto, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Michigan School of Public Health</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Michigan School of Public Heatlh</name>
      <address>
        <city>Ann Arbor</city>
        <state>Michigan</state>
        <zip>48109</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Western Michigan University Health Services</name>
      <address>
        <city>Kalamazoo</city>
        <state>Michigan</state>
        <zip>49008</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Central Michigan University Health Services</name>
      <address>
        <city>Mount Pleasant</city>
        <state>Michigan</state>
        <zip>48859</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Eastern Michigan University Health Services</name>
      <address>
        <city>Ypsilanti</city>
        <state>Michigan</state>
        <zip>48197</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Ohmit SE, Victor JC, Rotthoff JR, Teich ER, Truscon RK, Baum LL, Rangarajan B, Newton DW, Boulton ML, Monto AS. Prevention of antigenically drifted influenza by inactivated and live attenuated vaccines. N Engl J Med. 2006 Dec 14;355(24):2513-22.</citation>
    <PMID>17167134</PMID>
  </reference>
  <results_reference>
    <citation>Monto AS, Ohmit SE, Petrie JG, Johnson E, Truscon R, Teich E, Rotthoff J, Boulton M, Victor JC. Comparative efficacy of inactivated and live attenuated influenza vaccines. N Engl J Med. 2009 Sep 24;361(13):1260-7. doi: 10.1056/NEJMoa0808652.</citation>
    <PMID>19776407</PMID>
  </results_reference>
  <results_reference>
    <citation>Monto AS, Petrie JG, Cross RT, Johnson E, Liu M, Zhong W, Levine M, Katz JM, Ohmit SE. Antibody to Influenza Virus Neuraminidase: An Independent Correlate of Protection. J Infect Dis. 2015 Oct 15;212(8):1191-9. doi: 10.1093/infdis/jiv195. Epub 2015 Apr 8.</citation>
    <PMID>25858957</PMID>
  </results_reference>
  <results_reference>
    <citation>Ohmit SE, Petrie JG, Cross RT, Johnson E, Monto AS. Influenza hemagglutination-inhibition antibody titer as a correlate of vaccine-induced protection. J Infect Dis. 2011 Dec 15;204(12):1879-85. doi: 10.1093/infdis/jir661. Epub 2011 Oct 12.</citation>
    <PMID>21998477</PMID>
  </results_reference>
  <verification_date>November 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 1, 2007</study_first_submitted>
  <study_first_submitted_qc>October 1, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 2, 2007</study_first_posted>
  <results_first_submitted>August 8, 2011</results_first_submitted>
  <results_first_submitted_qc>August 8, 2011</results_first_submitted_qc>
  <results_first_posted type="Estimate">September 12, 2011</results_first_posted>
  <last_update_submitted>November 1, 2017</last_update_submitted>
  <last_update_submitted_qc>November 1, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">December 6, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Michigan</investigator_affiliation>
    <investigator_full_name>Arnold S. Monto</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>Influenza</keyword>
  <keyword>Live attenuated influenza vaccine</keyword>
  <keyword>Inactivated influenza vaccine</keyword>
  <keyword>Vaccine Efficacy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Influenza, Human</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vaccines</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Fluzone - Trivalent Inactivated Influenza Vaccine</title>
          <description>the trivalent inactivated influenza vaccine - Fluzone, manufactured by Sanofi-Pasteur</description>
        </group>
        <group group_id="P2">
          <title>Flumist - Live-attenuated Influenza Vaccine</title>
          <description>live-attenuated influenza vaccine Flumist, manufactured by MedImmune</description>
        </group>
        <group group_id="P3">
          <title>Placebo</title>
          <description>Physiologic saline administered as a nasal spray or intramuscular injection</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="814"/>
                <participants group_id="P2" count="813"/>
                <participants group_id="P3" count="325"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="787"/>
                <participants group_id="P2" count="783"/>
                <participants group_id="P3" count="312"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="27"/>
                <participants group_id="P2" count="30"/>
                <participants group_id="P3" count="13"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Fluzone - Trivalent Inactivated Influenza Vaccine</title>
          <description>the trivalent inactivated influenza vaccine - Fluzone, manufactured by Sanofi-Pasteur</description>
        </group>
        <group group_id="B2">
          <title>Flumist - Live-attenuated Influenza Vaccine</title>
          <description>live-attenuated influenza vaccine Flumist, manufactured by MedImmune</description>
        </group>
        <group group_id="B3">
          <title>Placebo</title>
          <description>Physiologic saline administered as a nasal spray or intramuscular injection</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="814"/>
            <count group_id="B2" value="813"/>
            <count group_id="B3" value="325"/>
            <count group_id="B4" value="1952"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="814"/>
                    <measurement group_id="B2" value="813"/>
                    <measurement group_id="B3" value="325"/>
                    <measurement group_id="B4" value="1952"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="23.2" spread="7.4"/>
                    <measurement group_id="B2" value="23.5" spread="7.7"/>
                    <measurement group_id="B3" value="22.9" spread="6.7"/>
                    <measurement group_id="B4" value="23.3" spread="7.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="494"/>
                    <measurement group_id="B2" value="519"/>
                    <measurement group_id="B3" value="201"/>
                    <measurement group_id="B4" value="1214"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="320"/>
                    <measurement group_id="B2" value="294"/>
                    <measurement group_id="B3" value="124"/>
                    <measurement group_id="B4" value="738"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="814"/>
                    <measurement group_id="B2" value="813"/>
                    <measurement group_id="B3" value="325"/>
                    <measurement group_id="B4" value="1952"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Laboratory-confirmed (Culture and/or PCR) Symptomatic Influenza</title>
        <time_frame>one influenza season - 2007-2008</time_frame>
        <population>ITT</population>
        <group_list>
          <group group_id="O1">
            <title>Fluzone - Trivalent Inactivated Influenza Vaccine</title>
            <description>the trivalent inactivated influenza vaccine - Fluzone, manufactured by Sanofi-Pasteur</description>
          </group>
          <group group_id="O2">
            <title>Flumist - Live-attenuated Influenza Vaccine</title>
            <description>live-attenuated influenza vaccine Flumist, manufactured by MedImmune</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Physiologic saline administered as a nasal spray or intramuscular injection</description>
          </group>
        </group_list>
        <measure>
          <title>Laboratory-confirmed (Culture and/or PCR) Symptomatic Influenza</title>
          <population>ITT</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="814"/>
                <count group_id="O2" value="813"/>
                <count group_id="O3" value="325"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="28"/>
                    <measurement group_id="O2" value="56"/>
                    <measurement group_id="O3" value="35"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Measure Immune Response Induced by the Vaccines and Identify Serologic Correlates of Immune Protection</title>
        <description>Measure immune response induced by the vaccines. Response was defined as greater than or equal to 4 fold rise in antibody titers measured by hemagglutination inhibition (HAI), microneutralization (MN), or neuraminidase inhibition (NAI) assays between sera collected at the prevaccination visit and those collected at the postvaccination visit.</description>
        <time_frame>Time between prevaccination visit and postvaccination visit; typically about 30 days.</time_frame>
        <population>Protocol only required that a subset of all specimens be run in order to get statistically significant outcomes; because the MN assay is labor intensive a subset of sera was processed in that assay for the Flumist-live attenuated influenza vaccine group to maintain comparable tested sample sizes among the three arms.</population>
        <group_list>
          <group group_id="O1">
            <title>Fluzone - Trivalent Inactivated Influenza Vaccine</title>
            <description>the trivalent inactivated influenza vaccine - Fluzone, manufactured by Sanofi-Pasteur</description>
          </group>
          <group group_id="O2">
            <title>Flumist - Live-attenuated Influenza Vaccine</title>
            <description>live-attenuated influenza vaccine Flumist, manufactured by MedImmune</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Physiologic saline administered as a nasal spray or intramuscular injection</description>
          </group>
        </group_list>
        <measure>
          <title>Measure Immune Response Induced by the Vaccines and Identify Serologic Correlates of Immune Protection</title>
          <description>Measure immune response induced by the vaccines. Response was defined as greater than or equal to 4 fold rise in antibody titers measured by hemagglutination inhibition (HAI), microneutralization (MN), or neuraminidase inhibition (NAI) assays between sera collected at the prevaccination visit and those collected at the postvaccination visit.</description>
          <population>Protocol only required that a subset of all specimens be run in order to get statistically significant outcomes; because the MN assay is labor intensive a subset of sera was processed in that assay for the Flumist-live attenuated influenza vaccine group to maintain comparable tested sample sizes among the three arms.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="178"/>
                <count group_id="O2" value="227"/>
                <count group_id="O3" value="92"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>HAI assay</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="178"/>
                    <count group_id="O2" value="227"/>
                    <count group_id="O3" value="92"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="137"/>
                    <measurement group_id="O2" value="48"/>
                    <measurement group_id="O3" value="92"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>NAI assay</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="178"/>
                    <count group_id="O2" value="227"/>
                    <count group_id="O3" value="92"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="65"/>
                    <measurement group_id="O2" value="14"/>
                    <measurement group_id="O3" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>MN assay</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="52"/>
                    <count group_id="O2" value="60"/>
                    <count group_id="O3" value="59"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="35"/>
                    <measurement group_id="O2" value="10"/>
                    <measurement group_id="O3" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Immune Response to Vaccination and Infection</title>
        <description>Response was defined as greater than or equal to 4 fold rise in antibody titers measured by hemagglutination inhibition (HAI), microneutralization (MN), or neuraminidase inhibition (NAI) assays between sera collected at the postvaccination visit and those collected at the postseason visit.</description>
        <time_frame>Postvaccination to postseason visit; typically about 3 months.</time_frame>
        <population>Protocol only required that a subset of all specimens be run in order to get statistically significant outcomes; because the MN assay is labor intensive a subset of sera was processed in that assay for the Flumist-live attenuated influenza vaccine group to maintain comparable tested sample sizes among the three arms.</population>
        <group_list>
          <group group_id="O1">
            <title>Fluzone - Trivalent Inactivated Influenza Vaccine</title>
            <description>the trivalent inactivated influenza vaccine - Fluzone, manufactured by Sanofi-Pasteur</description>
          </group>
          <group group_id="O2">
            <title>Flumist - Live-attenuated Influenza Vaccine</title>
            <description>live-attenuated influenza vaccine Flumist, manufactured by MedImmune</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Physiologic saline administered as a nasal spray or intramuscular injection</description>
          </group>
        </group_list>
        <measure>
          <title>Immune Response to Vaccination and Infection</title>
          <description>Response was defined as greater than or equal to 4 fold rise in antibody titers measured by hemagglutination inhibition (HAI), microneutralization (MN), or neuraminidase inhibition (NAI) assays between sera collected at the postvaccination visit and those collected at the postseason visit.</description>
          <population>Protocol only required that a subset of all specimens be run in order to get statistically significant outcomes; because the MN assay is labor intensive a subset of sera was processed in that assay for the Flumist-live attenuated influenza vaccine group to maintain comparable tested sample sizes among the three arms.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="22"/>
                <count group_id="O2" value="52"/>
                <count group_id="O3" value="29"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>HAI assay</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="22"/>
                    <count group_id="O2" value="52"/>
                    <count group_id="O3" value="29"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="40"/>
                    <measurement group_id="O3" value="28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>NAI assay</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="22"/>
                    <count group_id="O2" value="52"/>
                    <count group_id="O3" value="29"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9"/>
                    <measurement group_id="O2" value="33"/>
                    <measurement group_id="O3" value="22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>MN assay</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="22"/>
                    <count group_id="O2" value="30"/>
                    <count group_id="O3" value="29"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                    <measurement group_id="O2" value="20"/>
                    <measurement group_id="O3" value="26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Identify Serologic Correlates of Immune Protection. Suggest Changing to: Number of Participants Demonstrating Postvaccination Seroconversion.</title>
        <description>Identify serologic correlates of immune protection. Seroconversion is defined as either prevaccination titer of less than 8 and postvaccination titer of greater than or equal to 32 or prevaccination titer of greater than or equal to 8 and greater than or equal to 4 fold rise in strain specific hemagglutination-inhibition (HAI) antibody titer between prevaccination and postvaccination sera. Data is shown separately for cases (subjects with symptomatic influenza A laboratory confirmed by isolation in cell culture or identification in real-time polymerase chain reaction (PCR) assay) and non-cases (subjects without cell culture, real time PCR or serologic evidence of influenza infection).</description>
        <time_frame>Time between prevaccination and postvaccination, typically about 30 days.</time_frame>
        <population>Protocol only required that a subset of all specimens be run in order to get statistically significant outcomes; because the MN assay is labor intensive a subset of sera was processed in that assay for the Flumist-live attenuated influenza vaccine group to maintain comparable tested sample sizes among the three arms.</population>
        <group_list>
          <group group_id="O1">
            <title>Fluzone - Trivalent Inactivated Influenza Vaccine</title>
            <description>the trivalent inactivated influenza vaccine - Fluzone, manufactured by Sanofi-Pasteur</description>
          </group>
          <group group_id="O2">
            <title>Flumist - Live-attenuated Influenza Vaccine</title>
            <description>live-attenuated influenza vaccine Flumist, manufactured by MedImmune</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Physiologic saline administered as a nasal spray or intramuscular injection</description>
          </group>
        </group_list>
        <measure>
          <title>Identify Serologic Correlates of Immune Protection. Suggest Changing to: Number of Participants Demonstrating Postvaccination Seroconversion.</title>
          <description>Identify serologic correlates of immune protection. Seroconversion is defined as either prevaccination titer of less than 8 and postvaccination titer of greater than or equal to 32 or prevaccination titer of greater than or equal to 8 and greater than or equal to 4 fold rise in strain specific hemagglutination-inhibition (HAI) antibody titer between prevaccination and postvaccination sera. Data is shown separately for cases (subjects with symptomatic influenza A laboratory confirmed by isolation in cell culture or identification in real-time polymerase chain reaction (PCR) assay) and non-cases (subjects without cell culture, real time PCR or serologic evidence of influenza infection).</description>
          <population>Protocol only required that a subset of all specimens be run in order to get statistically significant outcomes; because the MN assay is labor intensive a subset of sera was processed in that assay for the Flumist-live attenuated influenza vaccine group to maintain comparable tested sample sizes among the three arms.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="259"/>
                <count group_id="O2" value="289"/>
                <count group_id="O3" value="110"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Cases</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="22"/>
                    <count group_id="O2" value="53"/>
                    <count group_id="O3" value="30"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="20"/>
                    <measurement group_id="O2" value="13"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Noncases</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="237"/>
                    <count group_id="O2" value="236"/>
                    <count group_id="O3" value="80"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="178"/>
                    <measurement group_id="O2" value="48"/>
                    <measurement group_id="O3" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>6 months</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Fluzone - Trivalent Inactivated Influenza Vaccine</title>
          <description>the trivalent inactivated influenza vaccine - Fluzone, manufactured by Sanofi-Pasteur</description>
        </group>
        <group group_id="E2">
          <title>Flumist - Live-attenuated Influenza Vaccine</title>
          <description>live-attenuated influenza vaccine Flumist, manufactured by MedImmune</description>
        </group>
        <group group_id="E3">
          <title>Placebo</title>
          <description>Physiologic saline administered as a nasal spray or intramuscular injection</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="814"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="813"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="325"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal pain, vomiting, diarrhea</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="814"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="813"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="325"/>
              </event>
              <event>
                <sub_title>Anorexia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="814"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="813"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="325"/>
              </event>
              <event>
                <sub_title>Appendicitis, appendectomy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="814"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="813"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="325"/>
              </event>
              <event>
                <sub_title>Appendectomy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="814"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="813"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="325"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Cholecystitis, cholecystectomy, cholelithiasis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="814"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="813"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="325"/>
              </event>
              <event>
                <sub_title>Cholecystitis, cholecystectomy, cholelithiasis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="814"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="813"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="325"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Mononucleosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="814"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="813"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="325"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>surgical repair of torn ACL</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="814"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="813"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="325"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Depression/anxiety</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="814"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="813"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="325"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Breast Cancer/Mastectomy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="814"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="813"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="325"/>
              </event>
              <event>
                <sub_title>Cervical cancer</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="814"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="813"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="325"/>
              </event>
              <event>
                <sub_title>surgury - remove tumor in left ovary/fallopian tube</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="814"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="813"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="325"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Pneumothorax</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="814"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="813"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="325"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Cellulitis left leg</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="814"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="813"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="325"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Surgical and medical procedures</title>
            <event_list>
              <event>
                <sub_title>Head injury bike accident</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="814"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="813"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="325"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="814"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="813"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="325"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Arnold S. Monto, MD</name_or_title>
      <organization>University of Michigan School of Public Health</organization>
      <phone>734-764-5453</phone>
      <email>asmonto@umich.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

